StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Madrigal Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$197.72M. For fiscal 2025 it was -$189.55M. The highest annual figure on record is -$3.14M in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$189.55M–
FY2024Dec 31, 2024-$455.57M–
FY2023Dec 31, 2023-$324.23M–
FY2022Dec 31, 2022-$224.86M–
FY2021Dec 31, 2021-$183.92M–
FY2020Dec 31, 2020-$157.56M–
FY2019Dec 31, 2019-$41.62M–
FY2018Dec 31, 2018-$25.51M–
FY2017Dec 31, 2017-$22.32M–
FY2016Dec 31, 2016-$17.61M–
FY2015Dec 31, 2015-$3.14M–
FY2014Dec 31, 2014-$78.93M–
FY2013Dec 31, 2013-$77.41M–
FY2012Dec 31, 2012-$54.14M–
FY2011Dec 31, 2011-$47.30M–
FY2010Dec 31, 2010-$38.20M–
FY2009Dec 31, 2009-$26.81M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.33M–
Q1 FY2026Mar 31, 2026-$167.44M–
Q4 FY2025Dec 31, 2025-$133.46M–
Q3 FY2025Sep 30, 2025$79.85M–
Q2 FY2025Jun 30, 2025-$47.05M–
Q1 FY2025Mar 31, 2025-$88.89M–
Q4 FY2024Dec 31, 2024-$104.49M–
Q3 FY2024Sep 30, 2024-$66.98M–
Q2 FY2024Jun 30, 2024-$134.95M–
Q1 FY2024Mar 31, 2024-$149.16M–
Q4 FY2023Dec 31, 2023-$79.93M–
Q3 FY2023Sep 30, 2023-$84.92M–
Q2 FY2023Jun 30, 2023-$75.31M–
Q1 FY2023Mar 31, 2023-$84.07M–
Q4 FY2022Dec 31, 2022-$58.52M–
Q3 FY2022Sep 30, 2022-$59.07M–
Q2 FY2022Jun 30, 2022-$57.36M–
Q1 FY2022Mar 31, 2022-$49.91M–
Q4 FY2021Dec 31, 2021-$48.05M–
Q3 FY2021Sep 30, 2021-$45.56M–
Q2 FY2021Jun 30, 2021-$46.88M–
Q1 FY2021Mar 31, 2021-$43.43M–
Q4 FY2020Dec 31, 2020-$54.95M–
Q3 FY2020Sep 30, 2020-$47.85M–
Q2 FY2020Jun 30, 2020-$24.26M–
Q1 FY2020Mar 31, 2020-$30.51M–
Q4 FY2019Dec 31, 2019-$12.28M–
Q3 FY2019Sep 30, 2019-$11.32M–
Q2 FY2019Jun 30, 2019-$11.54M–
Q1 FY2019Mar 31, 2019-$6.48M–
Q4 FY2018Dec 31, 2018-$6.27M–
Q3 FY2018Sep 30, 2018-$5.24M–
Q2 FY2018Jun 30, 2018-$5.36M–
Q1 FY2018Mar 31, 2018-$8.64M–
Q4 FY2017Dec 31, 2017-$5.95M–
Q3 FY2017Sep 30, 2017-$4.95M–
Q2 FY2017Jun 30, 2017-$7.65M–
Q1 FY2017Mar 31, 2017-$3.77M–
Q4 FY2016Dec 31, 2016-$5.28M–
Q3 FY2016Sep 30, 2016-$9.24M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?